Ushbu ishga iqtibos qilgan ishlar

2 ta ish

Ish: A randomized phase II study with ilixadencel, a cell-based immune primer, plus sunitinib versus sunitinib alone in synchronous metastatic renal cell carcinoma.

1. Development of criteria for the selection of therapeutic effects on metastatic renal cell carcinoma considering the factors of tumor microenvironment.

   M.N. Tillyashaykhov, Tashkent, Uzbekistan, E.V. Boyko +3

   MaqolaRenal cell carcinoma treatmentExperimental and Сlinical Urology20230 iqtibos

   ABIABI:AkademIndex/openalex/2023.article.006571

2. Incorporation of immunotherapies and nanomedicine to better normalize angiogenesis-based cancer treatment

   Saade Abdalkareem Jasim, I.M. Farber, Sara Abdalrazzaq M. Noraldeen +7

   MaqolaAngiogenesis and VEGF in CancerMicrovascular Research20240 iqtibos

   ABIABI:AkademIndex/openalex/2024.article.003439